QLGN News and Press, Qualigen Therapeutics Inc. From 08/18/22

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...

Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q2 GAAP EPS of -$0.11 beats by $0.06 . Revenue of $1.4M (+25.0% Y/Y) beats by $0.05M . As of June 30, 2022, Qualigen Therapeutics had $9.7 million in cash. The Company believes its cash is sufficient to ...

Q2 2022 FastPack ® Sales increased approximately 28 %, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN- 247 oncology therapeutic programs and acquisition of majori...

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...

Qualigen Therapeutics ( NASDAQ: QLGN ) on Friday filed for a mixed shelf offering of up to $150M. The company disclosed the offering in a S-3 filing with the U.S. SEC after hours. The offering consists of a combination of common stock, preferred stock, debt securit...

Qualigen Therapeutics ( NASDAQ: QLGN ) on Wednesday said it would partner China-based Hande Sciences to scale-up manufacturing to support investigational new drug application enabling studies for its QN-302 inhibitor platform. QLGN is developing QN-302 as a potential treat...

CARLSBAD, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...

Qualigen Therapeutics (NASDAQ:QLGN) on Friday has filed for the secondary stock offering of its 8,161,312 common shares. It will comprise of 3,500,000 shares and 4,661,312 shares purchase warrants, exercisable to purchase shares of common stock. The biotech company made it clear it will not r...

CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today anno...

Qualigen Therapeutics (NASDAQ:QLGN -1.6%) said on Tuesday it had begun IND-enabling studies for its lead program, QN-302, to treat pancreatic cancer, and potentially prostate cancer and other solid tumors. The company said its Investigational New Drug, or IND-enabling...